| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tumor Suppressor Protein p53 | 75 | 2022 | 715 | 7.790 |
Why?
|
| Phosphoprotein Phosphatases | 20 | 2016 | 115 | 4.600 |
Why?
|
| Genes, p53 | 57 | 2013 | 213 | 4.420 |
Why?
|
| Neoplasms, Experimental | 24 | 2018 | 211 | 2.510 |
Why?
|
| Aging | 17 | 2017 | 1174 | 2.280 |
Why?
|
| Protein Phosphatase 2C | 21 | 2020 | 55 | 1.990 |
Why?
|
| DNA Repair | 15 | 2015 | 579 | 1.810 |
Why?
|
| DNA Damage | 22 | 2018 | 505 | 1.780 |
Why?
|
| Cell Transformation, Neoplastic | 18 | 2017 | 617 | 1.640 |
Why?
|
| Gene Expression Regulation, Neoplastic | 20 | 2021 | 1870 | 1.630 |
Why?
|
| Tumor Suppressor Proteins | 12 | 2018 | 467 | 1.380 |
Why?
|
| Neoplasms | 20 | 2022 | 2757 | 1.350 |
Why?
|
| Mice | 127 | 2022 | 17492 | 1.330 |
Why?
|
| Osteosarcoma | 10 | 2016 | 257 | 1.270 |
Why?
|
| Mutation | 39 | 2022 | 5773 | 1.230 |
Why?
|
| Longevity | 6 | 2009 | 138 | 1.200 |
Why?
|
| Genes, Tumor Suppressor | 9 | 2014 | 202 | 1.180 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 9 | 2020 | 93 | 1.160 |
Why?
|
| Loss of Heterozygosity | 12 | 2019 | 124 | 1.080 |
Why?
|
| Cell Cycle Proteins | 9 | 2014 | 647 | 1.060 |
Why?
|
| Animals | 139 | 2022 | 33752 | 1.040 |
Why?
|
| Bone Neoplasms | 9 | 2017 | 427 | 0.970 |
Why?
|
| Neoplasm Proteins | 12 | 2006 | 667 | 0.960 |
Why?
|
| Mice, Knockout | 43 | 2015 | 3718 | 0.920 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 12 | 2013 | 79 | 0.920 |
Why?
|
| Disease Models, Animal | 22 | 2022 | 4275 | 0.910 |
Why?
|
| Cell Cycle | 11 | 2015 | 614 | 0.880 |
Why?
|
| Mammary Neoplasms, Experimental | 12 | 2010 | 244 | 0.860 |
Why?
|
| Cell Proliferation | 12 | 2020 | 2306 | 0.780 |
Why?
|
| Carcinogens | 9 | 2007 | 153 | 0.760 |
Why?
|
| Signal Transduction | 17 | 2017 | 4493 | 0.760 |
Why?
|
| Animals, Genetically Modified | 4 | 2014 | 316 | 0.760 |
Why?
|
| Mice, Transgenic | 41 | 2015 | 2390 | 0.750 |
Why?
|
| Serine | 3 | 2020 | 172 | 0.730 |
Why?
|
| DNA-Binding Proteins | 13 | 2016 | 2047 | 0.730 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2020 | 58 | 0.680 |
Why?
|
| Nuclear Proteins | 10 | 2013 | 1266 | 0.650 |
Why?
|
| Databases, Nucleic Acid | 1 | 2019 | 69 | 0.650 |
Why?
|
| Cellular Senescence | 8 | 2011 | 161 | 0.640 |
Why?
|
| Proto-Oncogene Proteins | 15 | 2013 | 550 | 0.620 |
Why?
|
| Mice, Inbred C57BL | 33 | 2018 | 4348 | 0.620 |
Why?
|
| Apoptosis | 17 | 2017 | 1781 | 0.620 |
Why?
|
| Zebrafish Proteins | 6 | 2000 | 105 | 0.620 |
Why?
|
| Lymphoma | 8 | 2011 | 321 | 0.600 |
Why?
|
| Histones | 5 | 2015 | 526 | 0.580 |
Why?
|
| Phosphorylation | 14 | 2020 | 1610 | 0.570 |
Why?
|
| Fibroblasts | 10 | 2013 | 878 | 0.570 |
Why?
|
| Heterozygote | 19 | 2010 | 672 | 0.570 |
Why?
|
| Adaptor Proteins, Signal Transducing | 5 | 2015 | 531 | 0.560 |
Why?
|
| DNA Breaks, Double-Stranded | 3 | 2015 | 124 | 0.510 |
Why?
|
| Carcinoma | 4 | 2013 | 278 | 0.480 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2013 | 156 | 0.470 |
Why?
|
| Phenotype | 15 | 2022 | 4227 | 0.450 |
Why?
|
| Insulin-Like Growth Factor I | 5 | 2009 | 340 | 0.450 |
Why?
|
| Recombination, Genetic | 10 | 2007 | 442 | 0.450 |
Why?
|
| Carcinogenicity Tests | 6 | 2009 | 20 | 0.440 |
Why?
|
| Alleles | 19 | 2015 | 1603 | 0.430 |
Why?
|
| Gene Silencing | 2 | 2018 | 237 | 0.430 |
Why?
|
| Mice, Mutant Strains | 9 | 2014 | 381 | 0.430 |
Why?
|
| Humans | 93 | 2022 | 123163 | 0.420 |
Why?
|
| Base Sequence | 30 | 2016 | 3091 | 0.420 |
Why?
|
| Cell Line, Tumor | 16 | 2018 | 3273 | 0.400 |
Why?
|
| Gene Expression Profiling | 6 | 2015 | 1682 | 0.400 |
Why?
|
| Germ-Line Mutation | 2 | 2014 | 313 | 0.400 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2012 | 94 | 0.390 |
Why?
|
| Gene Deletion | 7 | 2009 | 794 | 0.390 |
Why?
|
| Lung Neoplasms | 4 | 2017 | 1582 | 0.390 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2012 | 111 | 0.390 |
Why?
|
| Stem Cells | 9 | 2011 | 700 | 0.380 |
Why?
|
| Oncogenes | 2 | 2022 | 168 | 0.380 |
Why?
|
| Models, Biological | 9 | 2013 | 1441 | 0.370 |
Why?
|
| RNA, Messenger | 12 | 2014 | 2814 | 0.360 |
Why?
|
| Inflammation | 2 | 2017 | 1402 | 0.360 |
Why?
|
| Mutagens | 2 | 2001 | 84 | 0.360 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2009 | 81 | 0.350 |
Why?
|
| Sarcoma, Experimental | 5 | 2015 | 16 | 0.340 |
Why?
|
| MicroRNAs | 5 | 2019 | 827 | 0.340 |
Why?
|
| Genetic Engineering | 2 | 2009 | 161 | 0.340 |
Why?
|
| Molecular Sequence Data | 31 | 2016 | 3868 | 0.340 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2009 | 11 | 0.330 |
Why?
|
| Genetic Predisposition to Disease | 10 | 2013 | 3084 | 0.330 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2009 | 45 | 0.320 |
Why?
|
| Wnt Signaling Pathway | 3 | 2016 | 195 | 0.320 |
Why?
|
| Ultraviolet Rays | 7 | 2013 | 204 | 0.320 |
Why?
|
| Protein Kinases | 3 | 2006 | 330 | 0.310 |
Why?
|
| Sequence Deletion | 5 | 2002 | 527 | 0.310 |
Why?
|
| Colorectal Neoplasms | 2 | 2013 | 560 | 0.310 |
Why?
|
| Cyclins | 7 | 2002 | 101 | 0.310 |
Why?
|
| Adenocarcinoma | 5 | 2016 | 993 | 0.310 |
Why?
|
| Genetic Vectors | 10 | 2010 | 940 | 0.300 |
Why?
|
| Biomarkers, Tumor | 3 | 2017 | 1430 | 0.300 |
Why?
|
| Peptide Fragments | 2 | 2013 | 747 | 0.300 |
Why?
|
| DNA, Viral | 8 | 1997 | 478 | 0.300 |
Why?
|
| DNA | 5 | 2010 | 1592 | 0.290 |
Why?
|
| Oncogene Proteins | 1 | 2008 | 137 | 0.290 |
Why?
|
| HIV-1 | 6 | 1997 | 465 | 0.290 |
Why?
|
| RNA, Neoplasm | 3 | 2019 | 138 | 0.280 |
Why?
|
| Phosphoric Monoester Hydrolases | 2 | 2005 | 100 | 0.280 |
Why?
|
| Mammary Glands, Animal | 5 | 2007 | 482 | 0.280 |
Why?
|
| Genes, ras | 7 | 2017 | 96 | 0.280 |
Why?
|
| Retroviridae | 6 | 2003 | 194 | 0.280 |
Why?
|
| Stress, Physiological | 2 | 2009 | 260 | 0.270 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2011 | 533 | 0.270 |
Why?
|
| Morphogenesis | 1 | 2007 | 210 | 0.270 |
Why?
|
| Genotype | 18 | 2022 | 2541 | 0.270 |
Why?
|
| Tumor Suppressor Protein p14ARF | 2 | 2003 | 7 | 0.270 |
Why?
|
| Cell Division | 12 | 2002 | 780 | 0.260 |
Why?
|
| Transfection | 10 | 2007 | 1068 | 0.260 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2010 | 554 | 0.260 |
Why?
|
| Trans-Activators | 4 | 2013 | 809 | 0.260 |
Why?
|
| Cyclin D1 | 3 | 2003 | 111 | 0.260 |
Why?
|
| Gene Amplification | 4 | 2015 | 228 | 0.260 |
Why?
|
| Cisplatin | 2 | 2018 | 242 | 0.250 |
Why?
|
| Homeostasis | 5 | 2010 | 682 | 0.250 |
Why?
|
| Genetic Techniques | 2 | 2003 | 107 | 0.250 |
Why?
|
| Tamoxifen | 3 | 2012 | 363 | 0.240 |
Why?
|
| HEK293 Cells | 4 | 2020 | 740 | 0.240 |
Why?
|
| Embryonic and Fetal Development | 3 | 2002 | 132 | 0.240 |
Why?
|
| DNA Glycosylases | 1 | 2004 | 32 | 0.240 |
Why?
|
| Gene Dosage | 5 | 2001 | 441 | 0.230 |
Why?
|
| Liver Neoplasms | 6 | 2017 | 1308 | 0.230 |
Why?
|
| Cells, Cultured | 14 | 2013 | 3044 | 0.230 |
Why?
|
| Crosses, Genetic | 11 | 2004 | 162 | 0.230 |
Why?
|
| Methylnitrosourea | 2 | 2000 | 19 | 0.220 |
Why?
|
| Isoenzymes | 1 | 2004 | 223 | 0.220 |
Why?
|
| Mice, 129 Strain | 3 | 2014 | 98 | 0.220 |
Why?
|
| Point Mutation | 4 | 2004 | 348 | 0.220 |
Why?
|
| Drosophila melanogaster | 1 | 2009 | 738 | 0.220 |
Why?
|
| Doxorubicin | 4 | 2018 | 299 | 0.220 |
Why?
|
| Tumor Suppressor p53-Binding Protein 1 | 4 | 2010 | 12 | 0.210 |
Why?
|
| Drosophila Proteins | 1 | 2009 | 707 | 0.210 |
Why?
|
| Phosphopeptides | 2 | 2020 | 27 | 0.210 |
Why?
|
| Li-Fraumeni Syndrome | 4 | 2014 | 41 | 0.210 |
Why?
|
| Female | 45 | 2018 | 65489 | 0.210 |
Why?
|
| Homozygote | 8 | 2015 | 533 | 0.200 |
Why?
|
| Machine Learning | 2 | 2022 | 219 | 0.200 |
Why?
|
| Calculi | 1 | 2022 | 15 | 0.200 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 4 | 2006 | 130 | 0.200 |
Why?
|
| Polymerase Chain Reaction | 11 | 2005 | 1584 | 0.200 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2009 | 353 | 0.200 |
Why?
|
| Hematopoiesis | 2 | 2018 | 216 | 0.200 |
Why?
|
| Tumor Cells, Cultured | 8 | 2017 | 1061 | 0.190 |
Why?
|
| Stomach Neoplasms | 3 | 2007 | 538 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2011 | 101 | 0.190 |
Why?
|
| Nitrosamines | 3 | 2007 | 18 | 0.190 |
Why?
|
| Immune System | 1 | 2002 | 87 | 0.190 |
Why?
|
| Neoplasm Metastasis | 5 | 2016 | 650 | 0.190 |
Why?
|
| Genome, Human | 3 | 2018 | 1267 | 0.180 |
Why?
|
| Transcription Factors | 6 | 2016 | 2585 | 0.180 |
Why?
|
| Gene Targeting | 5 | 2003 | 179 | 0.180 |
Why?
|
| Phosphoproteins | 3 | 2009 | 399 | 0.180 |
Why?
|
| Genomic Instability | 4 | 2016 | 229 | 0.180 |
Why?
|
| Mitosis | 5 | 2004 | 238 | 0.180 |
Why?
|
| Gene Expression Regulation | 8 | 2009 | 2527 | 0.180 |
Why?
|
| RNA, Small Interfering | 5 | 2015 | 664 | 0.180 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2022 | 130 | 0.170 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2020 | 35 | 0.170 |
Why?
|
| Testis | 3 | 2015 | 405 | 0.170 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2012 | 113 | 0.170 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2012 | 254 | 0.170 |
Why?
|
| Breast Neoplasms | 5 | 2009 | 2477 | 0.170 |
Why?
|
| Mutagenesis | 4 | 2000 | 347 | 0.170 |
Why?
|
| Reproduction | 1 | 2002 | 243 | 0.170 |
Why?
|
| Genes, Retinoblastoma | 3 | 1997 | 18 | 0.170 |
Why?
|
| Gene Rearrangement | 2 | 2021 | 326 | 0.170 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2000 | 137 | 0.170 |
Why?
|
| Male | 37 | 2018 | 60082 | 0.170 |
Why?
|
| Sarcoma | 1 | 2022 | 194 | 0.170 |
Why?
|
| Protein Stability | 1 | 2020 | 165 | 0.160 |
Why?
|
| Thymus Neoplasms | 4 | 2004 | 29 | 0.160 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2013 | 262 | 0.160 |
Why?
|
| MCF-7 Cells | 1 | 2020 | 221 | 0.160 |
Why?
|
| Blotting, Western | 6 | 2013 | 1100 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2013 | 1292 | 0.160 |
Why?
|
| T-Lymphocytes | 7 | 2015 | 1676 | 0.160 |
Why?
|
| Cell Line | 14 | 2010 | 2771 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 6 | 2002 | 82 | 0.160 |
Why?
|
| Skin Aging | 2 | 2011 | 14 | 0.160 |
Why?
|
| Rhabdomyosarcoma | 1 | 2022 | 200 | 0.160 |
Why?
|
| Disease Progression | 4 | 2012 | 2026 | 0.160 |
Why?
|
| Ligases | 1 | 1998 | 46 | 0.160 |
Why?
|
| NIMA-Related Kinases | 1 | 2018 | 13 | 0.160 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2015 | 1012 | 0.160 |
Why?
|
| Aging, Premature | 2 | 2013 | 31 | 0.160 |
Why?
|
| Clone Cells | 1 | 2018 | 163 | 0.150 |
Why?
|
| Models, Genetic | 6 | 2022 | 766 | 0.150 |
Why?
|
| Wnt1 Protein | 6 | 2010 | 71 | 0.150 |
Why?
|
| Organ Specificity | 4 | 2010 | 423 | 0.150 |
Why?
|
| Wnt Proteins | 6 | 2000 | 198 | 0.150 |
Why?
|
| Recombinational DNA Repair | 1 | 2018 | 19 | 0.150 |
Why?
|
| ras Proteins | 2 | 2013 | 136 | 0.150 |
Why?
|
| Transcriptional Activation | 4 | 2015 | 481 | 0.150 |
Why?
|
| DNA Primers | 11 | 1998 | 661 | 0.150 |
Why?
|
| Sirtuins | 2 | 2009 | 20 | 0.150 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2000 | 274 | 0.150 |
Why?
|
| Neuroblastoma | 2 | 2015 | 509 | 0.150 |
Why?
|
| Aneuploidy | 2 | 1996 | 152 | 0.150 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 1998 | 70 | 0.150 |
Why?
|
| Adenomatous Polyposis Coli Protein | 2 | 2013 | 27 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2015 | 186 | 0.140 |
Why?
|
| Exome | 4 | 2015 | 1041 | 0.140 |
Why?
|
| Checkpoint Kinase 1 | 3 | 2006 | 24 | 0.140 |
Why?
|
| GTPase-Activating Proteins | 1 | 2017 | 85 | 0.140 |
Why?
|
| Quality Control | 1 | 2017 | 119 | 0.140 |
Why?
|
| Spleen | 2 | 2011 | 272 | 0.130 |
Why?
|
| Sarcoma, Ewing | 1 | 2017 | 113 | 0.130 |
Why?
|
| Promoter Regions, Genetic | 8 | 2014 | 1339 | 0.130 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2015 | 151 | 0.130 |
Why?
|
| Nerve Tissue Proteins | 2 | 2016 | 1116 | 0.130 |
Why?
|
| Moloney murine leukemia virus | 3 | 1996 | 19 | 0.130 |
Why?
|
| Liver Neoplasms, Experimental | 2 | 2007 | 60 | 0.130 |
Why?
|
| Duodenal Neoplasms | 1 | 2016 | 21 | 0.130 |
Why?
|
| Gene Regulatory Networks | 2 | 2015 | 351 | 0.130 |
Why?
|
| Sezary Syndrome | 1 | 2015 | 12 | 0.130 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 1 | 2015 | 9 | 0.130 |
Why?
|
| Amino Acid Sequence | 9 | 2005 | 2696 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2016 | 55 | 0.130 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 2830 | 0.120 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 1995 | 6 | 0.120 |
Why?
|
| Carrier Proteins | 2 | 2015 | 1019 | 0.120 |
Why?
|
| Ghrelin | 1 | 2015 | 51 | 0.120 |
Why?
|
| HeLa Cells | 4 | 2010 | 809 | 0.120 |
Why?
|
| Sirtuin 1 | 2 | 2013 | 47 | 0.120 |
Why?
|
| Uracil-DNA Glycosidase | 2 | 2004 | 5 | 0.120 |
Why?
|
| Skin Neoplasms | 3 | 2015 | 795 | 0.120 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 2 | 2013 | 34 | 0.120 |
Why?
|
| Genes, vif | 1 | 1994 | 1 | 0.120 |
Why?
|
| Cell Differentiation | 6 | 2015 | 1907 | 0.120 |
Why?
|
| Dipeptides | 1 | 2015 | 56 | 0.120 |
Why?
|
| Telomerase | 4 | 2014 | 161 | 0.120 |
Why?
|
| Aminopyridines | 1 | 2015 | 53 | 0.120 |
Why?
|
| Transcriptome | 3 | 2015 | 905 | 0.120 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2014 | 935 | 0.120 |
Why?
|
| Phospholipases A2, Calcium-Independent | 1 | 2014 | 13 | 0.120 |
Why?
|
| Receptor, Notch1 | 1 | 2014 | 66 | 0.120 |
Why?
|
| Programming, Linear | 1 | 2014 | 4 | 0.110 |
Why?
|
| DNA, Neoplasm | 5 | 2007 | 300 | 0.110 |
Why?
|
| 3' Untranslated Regions | 1 | 2014 | 165 | 0.110 |
Why?
|
| Mice, Inbred BALB C | 4 | 2009 | 1002 | 0.110 |
Why?
|
| HCT116 Cells | 2 | 2018 | 53 | 0.110 |
Why?
|
| Genes, pol | 2 | 1991 | 10 | 0.110 |
Why?
|
| Gamma Rays | 4 | 2010 | 48 | 0.110 |
Why?
|
| Biological Assay | 2 | 2005 | 100 | 0.110 |
Why?
|
| Sequence Homology, Nucleic Acid | 4 | 1994 | 287 | 0.110 |
Why?
|
| Brain Neoplasms | 2 | 2021 | 1235 | 0.110 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2013 | 256 | 0.110 |
Why?
|
| Casein Kinase Idelta | 1 | 2013 | 5 | 0.110 |
Why?
|
| Protein Phosphatase 1 | 2 | 2006 | 50 | 0.110 |
Why?
|
| Histone Deacetylase 1 | 1 | 2013 | 23 | 0.110 |
Why?
|
| Microsatellite Instability | 1 | 2013 | 36 | 0.110 |
Why?
|
| Prognosis | 4 | 2017 | 4507 | 0.110 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2013 | 54 | 0.110 |
Why?
|
| RNA, Long Noncoding | 1 | 2015 | 207 | 0.110 |
Why?
|
| S Phase | 1 | 2013 | 73 | 0.110 |
Why?
|
| CpG Islands | 2 | 2014 | 321 | 0.110 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 532 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 2 | 2016 | 673 | 0.100 |
Why?
|
| Gene Products, tax | 1 | 2013 | 46 | 0.100 |
Why?
|
| Antineoplastic Agents | 3 | 2018 | 1661 | 0.100 |
Why?
|
| G1 Phase | 1 | 2013 | 67 | 0.100 |
Why?
|
| Body Weight | 3 | 2011 | 1001 | 0.100 |
Why?
|
| Membrane Proteins | 2 | 2016 | 1530 | 0.100 |
Why?
|
| Radiation, Ionizing | 2 | 2003 | 42 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2012 | 15 | 0.100 |
Why?
|
| Embryo, Mammalian | 4 | 2013 | 452 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2015 | 863 | 0.100 |
Why?
|
| Genes, myc | 4 | 1996 | 98 | 0.100 |
Why?
|
| Gene Frequency | 2 | 2013 | 713 | 0.100 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2014 | 240 | 0.100 |
Why?
|
| Chromosome Mapping | 4 | 2007 | 1081 | 0.100 |
Why?
|
| Osteoblasts | 3 | 2015 | 149 | 0.100 |
Why?
|
| Caloric Restriction | 2 | 2010 | 84 | 0.100 |
Why?
|
| Transcription, Genetic | 5 | 2007 | 1695 | 0.100 |
Why?
|
| Cell Nucleus | 2 | 2012 | 675 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1994 | 473 | 0.090 |
Why?
|
| Chromosomal Proteins, Non-Histone | 2 | 2010 | 214 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2013 | 164 | 0.090 |
Why?
|
| Circadian Rhythm | 2 | 2010 | 269 | 0.090 |
Why?
|
| Chromosomal Instability | 1 | 2011 | 58 | 0.090 |
Why?
|
| Radiation Tolerance | 1 | 2011 | 52 | 0.090 |
Why?
|
| Gene Knockout Techniques | 1 | 2011 | 126 | 0.090 |
Why?
|
| Ribosomal Proteins | 1 | 2011 | 73 | 0.090 |
Why?
|
| Disease Susceptibility | 3 | 2007 | 297 | 0.090 |
Why?
|
| Sequence Alignment | 2 | 2004 | 623 | 0.090 |
Why?
|
| Exons | 3 | 2002 | 795 | 0.090 |
Why?
|
| Microscopy, Fluorescence | 1 | 2012 | 330 | 0.090 |
Why?
|
| Cerebellar Ataxia | 1 | 2011 | 65 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase Phosphatases | 1 | 2010 | 15 | 0.090 |
Why?
|
| Xeroderma Pigmentosum Group A Protein | 1 | 2010 | 3 | 0.090 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2010 | 22 | 0.090 |
Why?
|
| RNA-Binding Proteins | 1 | 2014 | 572 | 0.090 |
Why?
|
| Genetic Variation | 1 | 2017 | 1480 | 0.090 |
Why?
|
| Models, Animal | 2 | 2009 | 464 | 0.090 |
Why?
|
| Mice, Inbred Strains | 6 | 1998 | 311 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2010 | 30 | 0.090 |
Why?
|
| Germ Cells | 1 | 2011 | 192 | 0.090 |
Why?
|
| Whole-Body Irradiation | 1 | 2010 | 65 | 0.090 |
Why?
|
| Antigens, Nuclear | 1 | 2010 | 61 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 1262 | 0.090 |
Why?
|
| Kidney Neoplasms | 1 | 2014 | 432 | 0.090 |
Why?
|
| Gene Expression | 6 | 2016 | 1566 | 0.080 |
Why?
|
| Time Factors | 7 | 2007 | 6217 | 0.080 |
Why?
|
| Blotting, Southern | 8 | 2004 | 214 | 0.080 |
Why?
|
| Baculoviral IAP Repeat-Containing 3 Protein | 1 | 2009 | 5 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 3 | 2016 | 603 | 0.080 |
Why?
|
| Mammary Tumor Virus, Mouse | 3 | 1996 | 106 | 0.080 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2006 | 94 | 0.080 |
Why?
|
| B-Lymphocytes | 3 | 2004 | 518 | 0.080 |
Why?
|
| Cocarcinogenesis | 2 | 2000 | 23 | 0.080 |
Why?
|
| Heat-Shock Proteins | 2 | 2013 | 194 | 0.080 |
Why?
|
| Transforming Growth Factor alpha | 2 | 2000 | 27 | 0.080 |
Why?
|
| Karyotyping | 4 | 2015 | 330 | 0.080 |
Why?
|
| RNA-Directed DNA Polymerase | 6 | 1995 | 46 | 0.080 |
Why?
|
| Physical Conditioning, Animal | 1 | 2009 | 91 | 0.080 |
Why?
|
| Cell Count | 2 | 2006 | 250 | 0.080 |
Why?
|
| Histone Deacetylases | 1 | 2009 | 114 | 0.080 |
Why?
|
| G2 Phase | 2 | 2000 | 45 | 0.080 |
Why?
|
| Skin | 3 | 2013 | 505 | 0.070 |
Why?
|
| Histiocytic Disorders, Malignant | 1 | 2007 | 2 | 0.070 |
Why?
|
| Genes, Viral | 3 | 1989 | 183 | 0.070 |
Why?
|
| Ubiquitin-Specific Peptidase 7 | 1 | 2007 | 17 | 0.070 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2007 | 50 | 0.070 |
Why?
|
| Gene Products, tat | 3 | 1997 | 28 | 0.070 |
Why?
|
| Papilloma | 2 | 2000 | 25 | 0.070 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 761 | 0.070 |
Why?
|
| DNA Methylation | 2 | 2014 | 987 | 0.070 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2007 | 56 | 0.070 |
Why?
|
| Mice, Inbred NOD | 2 | 2018 | 285 | 0.070 |
Why?
|
| Estrogen Receptor alpha | 1 | 2010 | 450 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2007 | 50 | 0.070 |
Why?
|
| Colonic Neoplasms | 1 | 2010 | 245 | 0.070 |
Why?
|
| Epigenesis, Genetic | 2 | 2013 | 665 | 0.070 |
Why?
|
| Receptors, Notch | 1 | 2009 | 202 | 0.070 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2009 | 574 | 0.070 |
Why?
|
| Kinetics | 2 | 2007 | 1313 | 0.070 |
Why?
|
| Ubiquitin | 1 | 2007 | 141 | 0.070 |
Why?
|
| Pyridines | 2 | 2005 | 224 | 0.070 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2006 | 35 | 0.070 |
Why?
|
| Quinolines | 1 | 2007 | 96 | 0.070 |
Why?
|
| Cell Transformation, Viral | 2 | 2006 | 106 | 0.070 |
Why?
|
| Guanine | 1 | 2006 | 60 | 0.070 |
Why?
|
| Adenoma | 2 | 2000 | 133 | 0.070 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2006 | 55 | 0.060 |
Why?
|
| Hepatitis B virus | 3 | 2014 | 136 | 0.060 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2005 | 41 | 0.060 |
Why?
|
| RNA Interference | 1 | 2007 | 496 | 0.060 |
Why?
|
| Sequence Analysis, RNA | 2 | 2021 | 375 | 0.060 |
Why?
|
| Biochemistry | 1 | 2005 | 11 | 0.060 |
Why?
|
| Mice, SCID | 2 | 2017 | 571 | 0.060 |
Why?
|
| beta-Galactosidase | 1 | 2005 | 145 | 0.060 |
Why?
|
| Mice, Nude | 3 | 2015 | 694 | 0.060 |
Why?
|
| Virus Replication | 5 | 1997 | 603 | 0.060 |
Why?
|
| Mutation, Missense | 2 | 2015 | 847 | 0.060 |
Why?
|
| Repressor Proteins | 3 | 2005 | 811 | 0.060 |
Why?
|
| Foreign Bodies | 1 | 2006 | 104 | 0.060 |
Why?
|
| Oxidative Stress | 2 | 2010 | 796 | 0.060 |
Why?
|
| Molecular Biology | 1 | 2005 | 77 | 0.060 |
Why?
|
| Cloning, Molecular | 5 | 2003 | 892 | 0.060 |
Why?
|
| Lymphoma, T-Cell | 2 | 1995 | 64 | 0.060 |
Why?
|
| Uracil | 1 | 2004 | 14 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2015 | 757 | 0.060 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2004 | 66 | 0.060 |
Why?
|
| Threonine | 1 | 2004 | 59 | 0.060 |
Why?
|
| Gene Transfer Techniques | 2 | 2003 | 357 | 0.060 |
Why?
|
| Nitric Oxide Synthase | 1 | 2004 | 186 | 0.060 |
Why?
|
| Keratins | 2 | 2000 | 55 | 0.060 |
Why?
|
| Medulloblastoma | 1 | 2007 | 338 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2006 | 697 | 0.060 |
Why?
|
| Forecasting | 1 | 2005 | 354 | 0.060 |
Why?
|
| Indoles | 1 | 2005 | 180 | 0.060 |
Why?
|
| Chromosomes | 2 | 2004 | 198 | 0.060 |
Why?
|
| Genetic Loci | 2 | 2015 | 333 | 0.050 |
Why?
|
| Genes | 1 | 2004 | 444 | 0.050 |
Why?
|
| 1,2-Dimethylhydrazine | 1 | 2003 | 5 | 0.050 |
Why?
|
| Cell Movement | 2 | 2017 | 831 | 0.050 |
Why?
|
| Genes, fos | 2 | 2000 | 16 | 0.050 |
Why?
|
| Thiazolidinediones | 1 | 2003 | 79 | 0.050 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 3 | 1997 | 30 | 0.050 |
Why?
|
| Sex Factors | 1 | 2006 | 1259 | 0.050 |
Why?
|
| Hyperplasia | 3 | 1997 | 210 | 0.050 |
Why?
|
| DNA, Complementary | 1 | 2003 | 462 | 0.050 |
Why?
|
| Biomarkers | 2 | 2009 | 2946 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2017 | 1213 | 0.050 |
Why?
|
| Telomere | 2 | 2010 | 206 | 0.050 |
Why?
|
| DNA Mutational Analysis | 2 | 2014 | 793 | 0.050 |
Why?
|
| Wound Healing | 2 | 2006 | 452 | 0.050 |
Why?
|
| Flow Cytometry | 4 | 2013 | 803 | 0.050 |
Why?
|
| Body Constitution | 1 | 2002 | 37 | 0.050 |
Why?
|
| HIV | 1 | 2003 | 179 | 0.050 |
Why?
|
| Genetic Fitness | 1 | 2022 | 32 | 0.050 |
Why?
|
| Hair | 1 | 2002 | 23 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2007 | 651 | 0.050 |
Why?
|
| Lymphoma, AIDS-Related | 2 | 1992 | 37 | 0.050 |
Why?
|
| Mitotic Index | 2 | 1999 | 19 | 0.050 |
Why?
|
| Chromosome Deletion | 2 | 2015 | 638 | 0.050 |
Why?
|
| Receptors, Progesterone | 1 | 2005 | 865 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 809 | 0.050 |
Why?
|
| Selection, Genetic | 1 | 2022 | 155 | 0.050 |
Why?
|
| Animal Testing Alternatives | 1 | 2001 | 3 | 0.050 |
Why?
|
| Nuclease Protection Assays | 1 | 2000 | 1 | 0.050 |
Why?
|
| Cyclin G | 1 | 2000 | 2 | 0.050 |
Why?
|
| Cyclin G1 | 1 | 2000 | 2 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2002 | 473 | 0.050 |
Why?
|
| Cyclin B1 | 1 | 2000 | 9 | 0.050 |
Why?
|
| Biological Evolution | 1 | 2022 | 221 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2003 | 609 | 0.050 |
Why?
|
| Cyclin B | 1 | 2000 | 23 | 0.050 |
Why?
|
| Caseins | 1 | 2000 | 62 | 0.050 |
Why?
|
| Spermatogenesis | 1 | 2002 | 166 | 0.050 |
Why?
|
| Organ Size | 1 | 2002 | 412 | 0.050 |
Why?
|
| Gene Products, rev | 2 | 1997 | 11 | 0.050 |
Why?
|
| Osteoporosis | 1 | 2002 | 114 | 0.050 |
Why?
|
| Epidermis | 2 | 2000 | 60 | 0.040 |
Why?
|
| rev Gene Products, Human Immunodeficiency Virus | 2 | 1997 | 17 | 0.040 |
Why?
|
| Genomics | 2 | 2021 | 1478 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 383 | 0.040 |
Why?
|
| CDC2-CDC28 Kinases | 1 | 2000 | 21 | 0.040 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2000 | 110 | 0.040 |
Why?
|
| Cyclin E | 1 | 2000 | 30 | 0.040 |
Why?
|
| Centrosome | 1 | 2000 | 34 | 0.040 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2000 | 118 | 0.040 |
Why?
|
| Protein Phosphatase 2 | 1 | 2000 | 29 | 0.040 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2005 | 316 | 0.040 |
Why?
|
| Phylogeny | 1 | 2022 | 689 | 0.040 |
Why?
|
| Intestinal Neoplasms | 1 | 2000 | 39 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2002 | 262 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2005 | 1683 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2005 | 518 | 0.040 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2000 | 73 | 0.040 |
Why?
|
| Oncogene Protein p21(ras) | 2 | 1996 | 9 | 0.040 |
Why?
|
| Microsatellite Repeats | 2 | 2016 | 219 | 0.040 |
Why?
|
| Bromodeoxyuridine | 1 | 1999 | 60 | 0.040 |
Why?
|
| Precipitin Tests | 1 | 1999 | 151 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2000 | 1687 | 0.040 |
Why?
|
| Neurofibromin 2 | 1 | 1998 | 6 | 0.040 |
Why?
|
| Phosphotransferases | 1 | 1999 | 41 | 0.040 |
Why?
|
| Lymphocyte Activation | 3 | 2015 | 676 | 0.040 |
Why?
|
| WT1 Proteins | 1 | 1998 | 27 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 2 | 2014 | 752 | 0.040 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 3 | 2005 | 70 | 0.040 |
Why?
|
| BRCA2 Protein | 1 | 1998 | 43 | 0.040 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 1998 | 35 | 0.040 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2000 | 145 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 3 | 1996 | 766 | 0.040 |
Why?
|
| Retinoblastoma Protein | 1 | 1998 | 77 | 0.040 |
Why?
|
| Neurofibromin 1 | 1 | 1998 | 42 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 1998 | 67 | 0.040 |
Why?
|
| Adipose Tissue | 1 | 2002 | 464 | 0.040 |
Why?
|
| PubMed | 1 | 2018 | 21 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2018 | 94 | 0.040 |
Why?
|
| Actins | 1 | 2000 | 340 | 0.040 |
Why?
|
| Genes, tat | 2 | 1995 | 10 | 0.040 |
Why?
|
| Teratogens | 1 | 1999 | 87 | 0.040 |
Why?
|
| Neoplasm Transplantation | 2 | 2014 | 369 | 0.040 |
Why?
|
| Natural Language Processing | 1 | 2018 | 63 | 0.040 |
Why?
|
| Esophageal Neoplasms | 1 | 2002 | 359 | 0.040 |
Why?
|
| RNA, Viral | 2 | 1997 | 541 | 0.040 |
Why?
|
| Stomach | 1 | 2000 | 271 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 1999 | 240 | 0.040 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2017 | 31 | 0.040 |
Why?
|
| 3T3 Cells | 4 | 2003 | 129 | 0.040 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 1995 | 54 | 0.040 |
Why?
|
| Diet | 1 | 2004 | 1126 | 0.040 |
Why?
|
| Feedback, Physiological | 1 | 2017 | 69 | 0.040 |
Why?
|
| Cytoskeletal Proteins | 1 | 1998 | 269 | 0.040 |
Why?
|
| von Willebrand Factor | 1 | 1999 | 197 | 0.040 |
Why?
|
| Validation Studies as Topic | 1 | 2017 | 13 | 0.040 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 1996 | 135 | 0.040 |
Why?
|
| Algorithms | 2 | 2014 | 1592 | 0.040 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 2 | 1994 | 56 | 0.040 |
Why?
|
| Genome, Viral | 2 | 2014 | 170 | 0.040 |
Why?
|
| Transcription Factor AP-1 | 1 | 2017 | 106 | 0.040 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 1997 | 132 | 0.040 |
Why?
|
| p21-Activated Kinases | 1 | 2017 | 58 | 0.040 |
Why?
|
| Biocatalysis | 1 | 2016 | 33 | 0.030 |
Why?
|
| Oncogene Proteins v-fos | 1 | 1996 | 1 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 1998 | 269 | 0.030 |
Why?
|
| Proto-Oncogenes | 1 | 1996 | 37 | 0.030 |
Why?
|
| Incidence | 2 | 2002 | 3047 | 0.030 |
Why?
|
| Kidney | 2 | 2002 | 1337 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 1999 | 996 | 0.030 |
Why?
|
| Fetus | 1 | 2000 | 573 | 0.030 |
Why?
|
| Retroviridae Infections | 1 | 1996 | 10 | 0.030 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 1996 | 9 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 2016 | 283 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 1997 | 169 | 0.030 |
Why?
|
| Ampulla of Vater | 1 | 2016 | 16 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2017 | 215 | 0.030 |
Why?
|
| Gene Products, pol | 2 | 1995 | 5 | 0.030 |
Why?
|
| Kainic Acid | 1 | 1996 | 27 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 2007 | 371 | 0.030 |
Why?
|
| Genetic Drift | 1 | 2015 | 22 | 0.030 |
Why?
|
| Thymus Gland | 1 | 1996 | 99 | 0.030 |
Why?
|
| DNA Replication | 2 | 2013 | 342 | 0.030 |
Why?
|
| Genes, Lethal | 1 | 1995 | 76 | 0.030 |
Why?
|
| DNA Nucleotidyltransferases | 1 | 1995 | 18 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 350 | 0.030 |
Why?
|
| Genes, rev | 1 | 1995 | 5 | 0.030 |
Why?
|
| Astrocytes | 2 | 1995 | 251 | 0.030 |
Why?
|
| Caspase 2 | 1 | 2015 | 26 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2015 | 131 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2015 | 101 | 0.030 |
Why?
|
| Ataxia Telangiectasia | 1 | 1995 | 15 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 1997 | 345 | 0.030 |
Why?
|
| Viral Proteins | 2 | 1995 | 348 | 0.030 |
Why?
|
| Tumor Virus Infections | 1 | 1996 | 134 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2015 | 54 | 0.030 |
Why?
|
| Cell Death | 1 | 1996 | 243 | 0.030 |
Why?
|
| Cleavage Stimulation Factor | 1 | 2014 | 5 | 0.030 |
Why?
|
| vif Gene Products, Human Immunodeficiency Virus | 1 | 1994 | 2 | 0.030 |
Why?
|
| Gene Products, vif | 1 | 1994 | 4 | 0.030 |
Why?
|
| Serial Passage | 1 | 1994 | 19 | 0.030 |
Why?
|
| Genetic Complementation Test | 1 | 1994 | 87 | 0.030 |
Why?
|
| Chromosome Breakpoints | 1 | 2014 | 80 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 1995 | 133 | 0.030 |
Why?
|
| Japan | 1 | 2014 | 134 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 877 | 0.030 |
Why?
|
| Rats | 3 | 2013 | 3654 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2007 | 123 | 0.030 |
Why?
|
| Allografts | 1 | 2015 | 190 | 0.030 |
Why?
|
| Response Elements | 1 | 2014 | 97 | 0.030 |
Why?
|
| Polyadenylation | 1 | 2014 | 54 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 2014 | 131 | 0.030 |
Why?
|
| Software Design | 1 | 2014 | 24 | 0.030 |
Why?
|
| Toxicology | 1 | 1994 | 9 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2014 | 142 | 0.030 |
Why?
|
| Pituitary Neoplasms | 1 | 1995 | 83 | 0.030 |
Why?
|
| Dimethylnitrosamine | 1 | 1993 | 2 | 0.030 |
Why?
|
| Proviruses | 2 | 1996 | 17 | 0.030 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 1994 | 60 | 0.030 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 1993 | 37 | 0.030 |
Why?
|
| Creatine Kinase | 1 | 1993 | 54 | 0.030 |
Why?
|
| RNA, Antisense | 1 | 1993 | 35 | 0.030 |
Why?
|
| Oligonucleotides | 2 | 1991 | 88 | 0.030 |
Why?
|
| Diethylnitrosamine | 1 | 2013 | 16 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2015 | 327 | 0.030 |
Why?
|
| Pyrimidine Dimers | 1 | 2013 | 2 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 3 | 2000 | 68 | 0.030 |
Why?
|
| Proteins | 1 | 1998 | 1037 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 556 | 0.030 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2013 | 40 | 0.030 |
Why?
|
| Glioblastoma | 1 | 1997 | 334 | 0.030 |
Why?
|
| DNA, Mitochondrial | 1 | 2014 | 211 | 0.030 |
Why?
|
| Fibrosis | 1 | 1995 | 429 | 0.030 |
Why?
|
| Escherichia coli Proteins | 1 | 1995 | 303 | 0.030 |
Why?
|
| Androgens | 1 | 1995 | 256 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2014 | 271 | 0.030 |
Why?
|
| Astrocytoma | 1 | 1994 | 103 | 0.030 |
Why?
|
| Hepacivirus | 1 | 2014 | 241 | 0.030 |
Why?
|
| Defective Viruses | 2 | 1995 | 18 | 0.030 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 2013 | 62 | 0.030 |
Why?
|
| Autoantigens | 1 | 2013 | 119 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2015 | 864 | 0.030 |
Why?
|
| Protein Binding | 1 | 2016 | 1740 | 0.030 |
Why?
|
| Genetic Linkage | 2 | 2007 | 454 | 0.030 |
Why?
|
| Thyroid Neoplasms | 1 | 1995 | 197 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 198 | 0.030 |
Why?
|
| Mice, Inbred CBA | 1 | 1992 | 30 | 0.030 |
Why?
|
| Prostate | 1 | 1995 | 421 | 0.030 |
Why?
|
| Age Factors | 1 | 1999 | 2802 | 0.030 |
Why?
|
| DNA Transposable Elements | 2 | 1994 | 177 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 1993 | 290 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 459 | 0.020 |
Why?
|
| Cell Survival | 1 | 1994 | 806 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 428 | 0.020 |
Why?
|
| Blastocyst | 1 | 1992 | 76 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2014 | 475 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 1994 | 614 | 0.020 |
Why?
|
| Carcinogenesis | 1 | 2014 | 328 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2021 | 4705 | 0.020 |
Why?
|
| Pediatrics | 1 | 2021 | 1138 | 0.020 |
Why?
|
| Mutagenicity Tests | 1 | 2011 | 36 | 0.020 |
Why?
|
| Hyperpigmentation | 1 | 2011 | 13 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2001 | 3316 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 512 | 0.020 |
Why?
|
| Glioma | 1 | 1995 | 496 | 0.020 |
Why?
|
| Survival Rate | 1 | 2015 | 1996 | 0.020 |
Why?
|
| Ku Autoantigen | 1 | 2010 | 21 | 0.020 |
Why?
|
| Retroviruses, Simian | 1 | 1990 | 3 | 0.020 |
Why?
|
| Templates, Genetic | 1 | 1990 | 95 | 0.020 |
Why?
|
| Hippocampus | 1 | 1996 | 820 | 0.020 |
Why?
|
| Sympathetic Nervous System | 1 | 2010 | 62 | 0.020 |
Why?
|
| Haploinsufficiency | 1 | 2011 | 247 | 0.020 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2010 | 76 | 0.020 |
Why?
|
| Adult Stem Cells | 1 | 2010 | 53 | 0.020 |
Why?
|
| Simian Immunodeficiency Virus | 1 | 1990 | 92 | 0.020 |
Why?
|
| Growth Disorders | 1 | 2011 | 207 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 941 | 0.020 |
Why?
|
| Retroviridae Proteins | 1 | 1988 | 13 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2010 | 408 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 2 | 1996 | 368 | 0.020 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2009 | 62 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2014 | 1168 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 3249 | 0.020 |
Why?
|
| Endonucleases | 1 | 1988 | 55 | 0.020 |
Why?
|
| Cellular Reprogramming | 1 | 2010 | 115 | 0.020 |
Why?
|
| Reference Values | 2 | 2003 | 697 | 0.020 |
Why?
|
| Random Allocation | 1 | 2009 | 427 | 0.020 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2007 | 31 | 0.020 |
Why?
|
| Chromosomes, Mammalian | 1 | 2007 | 41 | 0.020 |
Why?
|
| Epithelial Cells | 2 | 2003 | 900 | 0.020 |
Why?
|
| Plasmids | 1 | 1988 | 509 | 0.020 |
Why?
|
| Anemia | 1 | 2011 | 340 | 0.020 |
Why?
|
| P-Selectin | 1 | 2007 | 77 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2007 | 258 | 0.020 |
Why?
|
| Enzyme Activation | 2 | 2000 | 617 | 0.020 |
Why?
|
| Autophagy | 1 | 2010 | 391 | 0.020 |
Why?
|
| Dermis | 1 | 2006 | 24 | 0.020 |
Why?
|
| Body Composition | 1 | 2009 | 513 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2007 | 396 | 0.020 |
Why?
|
| SAP90-PSD95 Associated Proteins | 1 | 2006 | 2 | 0.020 |
Why?
|
| Discs Large Homolog 1 Protein | 1 | 2006 | 8 | 0.020 |
Why?
|
| Child | 3 | 2015 | 24234 | 0.020 |
Why?
|
| Adult | 4 | 2015 | 29057 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2014 | 1000 | 0.020 |
Why?
|
| Multigene Family | 1 | 2007 | 298 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2007 | 394 | 0.020 |
Why?
|
| Biopolymers | 1 | 2005 | 20 | 0.020 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 2 | 1996 | 11 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 1995 | 1515 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 714 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 5046 | 0.020 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2006 | 74 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2009 | 1472 | 0.020 |
Why?
|
| Methylation | 1 | 2005 | 226 | 0.020 |
Why?
|
| Hemangiosarcoma | 1 | 2005 | 38 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2006 | 444 | 0.020 |
Why?
|
| Skin Diseases | 1 | 2006 | 123 | 0.020 |
Why?
|
| Mitochondria | 1 | 2010 | 677 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2007 | 455 | 0.020 |
Why?
|
| Animals, Newborn | 2 | 2000 | 991 | 0.020 |
Why?
|
| Glycine | 1 | 2005 | 167 | 0.010 |
Why?
|
| Protein Transport | 1 | 2006 | 369 | 0.010 |
Why?
|
| Steroids | 1 | 2005 | 201 | 0.010 |
Why?
|
| DNA Adducts | 1 | 2005 | 78 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2005 | 425 | 0.010 |
Why?
|
| Precancerous Conditions | 2 | 2000 | 287 | 0.010 |
Why?
|
| Imidazoles | 1 | 2005 | 199 | 0.010 |
Why?
|
| Luciferases | 2 | 1995 | 137 | 0.010 |
Why?
|
| Hemangioma | 1 | 2005 | 95 | 0.010 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2005 | 82 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2006 | 340 | 0.010 |
Why?
|
| Chromatin | 1 | 2007 | 552 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2005 | 287 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2006 | 459 | 0.010 |
Why?
|
| Arginine | 1 | 2005 | 303 | 0.010 |
Why?
|
| Ecdysterone | 1 | 2003 | 2 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 1226 | 0.010 |
Why?
|
| CCAAT-Enhancer-Binding Protein-alpha | 1 | 2003 | 14 | 0.010 |
Why?
|
| Adolescent | 2 | 2015 | 19102 | 0.010 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2003 | 35 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2004 | 171 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2003 | 126 | 0.010 |
Why?
|
| Progesterone | 1 | 2005 | 624 | 0.010 |
Why?
|
| Thiazoles | 1 | 2003 | 97 | 0.010 |
Why?
|
| Avian Sarcoma Viruses | 1 | 1982 | 32 | 0.010 |
Why?
|
| Bone Marrow | 2 | 1997 | 323 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 572 | 0.010 |
Why?
|
| Hair Color | 1 | 2002 | 12 | 0.010 |
Why?
|
| Gene Library | 1 | 2003 | 220 | 0.010 |
Why?
|
| Breast | 1 | 2003 | 214 | 0.010 |
Why?
|
| Fatty Liver | 1 | 2003 | 176 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2003 | 834 | 0.010 |
Why?
|
| Young Adult | 1 | 2015 | 8862 | 0.010 |
Why?
|
| Glycogen Synthase Kinases | 1 | 2000 | 6 | 0.010 |
Why?
|
| Activating Transcription Factor 2 | 1 | 2000 | 15 | 0.010 |
Why?
|
| Forelimb | 1 | 2000 | 14 | 0.010 |
Why?
|
| Aged | 1 | 2018 | 19080 | 0.010 |
Why?
|
| Integrin beta1 | 1 | 2000 | 54 | 0.010 |
Why?
|
| CD18 Antigens | 1 | 2000 | 49 | 0.010 |
Why?
|
| Pepsinogen A | 1 | 2000 | 17 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 2000 | 22 | 0.010 |
Why?
|
| Nocodazole | 1 | 2000 | 14 | 0.010 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2000 | 64 | 0.010 |
Why?
|
| Mice, Inbred ICR | 1 | 2000 | 147 | 0.010 |
Why?
|
| Piroxicam | 1 | 2000 | 2 | 0.010 |
Why?
|
| Eflornithine | 1 | 2000 | 15 | 0.010 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2000 | 8 | 0.010 |
Why?
|
| Benzene | 1 | 2000 | 24 | 0.010 |
Why?
|
| Genes, APC | 1 | 2000 | 13 | 0.010 |
Why?
|
| Osteocalcin | 1 | 2000 | 40 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2000 | 164 | 0.010 |
Why?
|
| DNA Restriction Enzymes | 1 | 1980 | 120 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2000 | 49 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2003 | 1070 | 0.010 |
Why?
|
| Superoxide Dismutase | 1 | 2000 | 140 | 0.010 |
Why?
|
| Motor Neurons | 1 | 2000 | 139 | 0.010 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2000 | 85 | 0.010 |
Why?
|
| Tubulin | 1 | 2000 | 106 | 0.010 |
Why?
|
| Hydroxyurea | 1 | 2000 | 81 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2000 | 211 | 0.010 |
Why?
|
| United States | 1 | 2014 | 10631 | 0.010 |
Why?
|
| Middle Aged | 1 | 2018 | 25992 | 0.010 |
Why?
|
| Chimera | 1 | 1998 | 88 | 0.010 |
Why?
|
| Spinal Cord | 1 | 2000 | 305 | 0.010 |
Why?
|
| Gastric Mucosa | 1 | 2000 | 483 | 0.010 |
Why?
|
| Motor Activity | 1 | 2000 | 522 | 0.010 |
Why?
|
| Genes, Regulator | 1 | 1997 | 56 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 1997 | 114 | 0.010 |
Why?
|
| Mitomycin | 1 | 1996 | 49 | 0.010 |
Why?
|
| Mitogens | 1 | 1996 | 30 | 0.010 |
Why?
|
| Mink Cell Focus-Inducing Viruses | 1 | 1996 | 1 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 1 | 1996 | 1 | 0.010 |
Why?
|
| Keratinocytes | 1 | 1996 | 60 | 0.010 |
Why?
|
| Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 1996 | 6 | 0.010 |
Why?
|
| RNA Polymerase III | 1 | 1996 | 39 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 1996 | 99 | 0.010 |
Why?
|
| CD3 Complex | 1 | 1996 | 82 | 0.010 |
Why?
|
| Lac Repressors | 1 | 1995 | 14 | 0.010 |
Why?
|
| Bacteriophage lambda | 1 | 1995 | 27 | 0.010 |
Why?
|
| Gene Products, gag | 1 | 1995 | 19 | 0.010 |
Why?
|
| HIV Reverse Transcriptase | 1 | 1995 | 12 | 0.010 |
Why?
|
| Genetic Heterogeneity | 1 | 1996 | 123 | 0.010 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 1995 | 4 | 0.010 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 1995 | 29 | 0.010 |
Why?
|
| Protamine Kinase | 1 | 1995 | 7 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 1996 | 147 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 1995 | 28 | 0.010 |
Why?
|
| Fibrosarcoma | 1 | 1995 | 28 | 0.010 |
Why?
|
| Transgenes | 1 | 1996 | 334 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 1997 | 290 | 0.010 |
Why?
|
| Inhibins | 1 | 1995 | 87 | 0.010 |
Why?
|
| Orchiectomy | 1 | 1995 | 44 | 0.010 |
Why?
|
| Oncogenic Viruses | 1 | 1975 | 17 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1995 | 74 | 0.010 |
Why?
|
| RNA Viruses | 1 | 1975 | 36 | 0.010 |
Why?
|
| Tyrosine | 1 | 1995 | 152 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 1995 | 248 | 0.010 |
Why?
|
| Frameshift Mutation | 1 | 1995 | 175 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1995 | 330 | 0.010 |
Why?
|
| Integrases | 1 | 1995 | 161 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 1997 | 388 | 0.010 |
Why?
|
| Zidovudine | 1 | 1994 | 22 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 1994 | 171 | 0.010 |
Why?
|
| Binding Sites | 1 | 1997 | 1291 | 0.010 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 1993 | 79 | 0.010 |
Why?
|
| Genome | 1 | 1996 | 472 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1993 | 188 | 0.010 |
Why?
|
| Infant | 1 | 2007 | 12347 | 0.010 |
Why?
|
| Genes, env | 1 | 1991 | 9 | 0.010 |
Why?
|
| Peptides | 1 | 1995 | 794 | 0.010 |
Why?
|
| Peptide Chain Initiation, Translational | 1 | 1991 | 20 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2007 | 13886 | 0.010 |
Why?
|
| Codon | 1 | 1991 | 96 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1992 | 391 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1992 | 312 | 0.010 |
Why?
|
| RNA | 1 | 1995 | 572 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 1995 | 522 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 1991 | 116 | 0.010 |
Why?
|
| Syndrome | 1 | 1993 | 1115 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 1995 | 879 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1991 | 401 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2007 | 16021 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1988 | 80 | 0.000 |
Why?
|
| DNA Probes | 1 | 1988 | 123 | 0.000 |
Why?
|
| China | 1 | 1988 | 240 | 0.000 |
Why?
|
| Pregnancy | 1 | 2001 | 7146 | 0.000 |
Why?
|
| DNA, Recombinant | 1 | 1987 | 100 | 0.000 |
Why?
|
| Helper Viruses | 1 | 1987 | 45 | 0.000 |
Why?
|
| Coturnix | 1 | 1982 | 5 | 0.000 |
Why?
|
| Avian Leukosis Virus | 1 | 1982 | 14 | 0.000 |
Why?
|
| Brain | 1 | 1994 | 2961 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1995 | 8106 | 0.000 |
Why?
|
| Risk Factors | 1 | 1994 | 10008 | 0.000 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 1975 | 15 | 0.000 |
Why?
|
| Chromatography | 1 | 1975 | 43 | 0.000 |
Why?
|
| Polyvinyls | 1 | 1975 | 13 | 0.000 |
Why?
|
| Evaluation Studies as Topic | 1 | 1975 | 258 | 0.000 |
Why?
|
| Culture Media | 1 | 1975 | 182 | 0.000 |
Why?
|